Janux Therapeutics, Inc. (JANX): Price and Financial Metrics
JANX Price/Volume Stats
| Current price | $54.39 | 52-week high | $65.60 |
| Prev. close | $53.99 | 52-week low | $5.65 |
| Day low | $52.67 | Volume | 572,900 |
| Day high | $55.93 | Avg. volume | 712,335 |
| 50-day MA | $48.06 | Dividend yield | N/A |
| 200-day MA | $40.71 | Market Cap | 2.84B |
JANX Stock Price Chart Interactive Chart >
Janux Therapeutics, Inc. (JANX) Company Bio
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...